{"id":"moxifloxacin-or-levofloxacin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL33","moleculeType":"Small molecule","molecularWeight":"361.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, moxifloxacin and levofloxacin prevent bacterial DNA replication and transcription, ultimately leading to bacterial cell death. This mechanism is effective against a wide range of bacteria, including both Gram-positive and Gram-negative species.","oneSentence":"Moxifloxacin and Levofloxacin are broad-spectrum antibiotics that inhibit DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:06.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Skin and skin structure infections"}]},"trialDetails":[{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":"Gram-negative Bacteremia","enrollment":2500},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting","enrollment":117911},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":"Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB","enrollment":1050},{"nctId":"NCT06081361","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-12-22","conditions":"Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":186},{"nctId":"NCT02754765","phase":"PHASE3","title":"Evaluating Newly Approved Drugs for Multidrug-resistant TB","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2016-12","conditions":"Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses","enrollment":754},{"nctId":"NCT03867136","phase":"PHASE4","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2020-06-01","conditions":"Multidrug Resistant Tuberculosis","enrollment":354},{"nctId":"NCT05893147","phase":"NA","title":"BALANCE+ Vanguard Phase","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-08-26","conditions":"Gram-negative Bacteremia","enrollment":174},{"nctId":"NCT06526039","phase":"PHASE3","title":"A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB","status":"NOT_YET_RECRUITING","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2024-07","conditions":"Tuberculosis, Pulmonary","enrollment":100},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02409290","phase":"PHASE3","title":"The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"IUATLD, Inc","startDate":"2016-03","conditions":"MDR-TB","enrollment":588},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Appendicitis","enrollment":1552},{"nctId":"NCT02454205","phase":"PHASE2, PHASE3","title":"An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2015-11-12","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis, Extensively-drug Resistant Tuberculosis","enrollment":154},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03257423","phase":"NA","title":"Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2017-04-04","conditions":"Acute Appendicitis","enrollment":200},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Keratitis; Infectious Disease (Manifestation)","enrollment":35},{"nctId":"NCT03535558","phase":"","title":"Fluoroquinolone Associated Disability","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-17","conditions":"Bronchitis, Sinusitis, Urinary Tract Infections","enrollment":239306},{"nctId":"NCT03625739","phase":"","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2018-07-01","conditions":"Tuberculosis","enrollment":800},{"nctId":"NCT02031588","phase":"","title":"Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-12","conditions":"Bacterial Infections","enrollment":77},{"nctId":"NCT00665327","phase":"PHASE4","title":"Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-11","conditions":"Pneumonia","enrollment":401},{"nctId":"NCT01434173","phase":"","title":"Risk of Acute Liver Injury in Users of Antimicrobials","status":"COMPLETED","sponsor":"Bayer","startDate":"2001-07","conditions":"Drug-Induced Liver Injury","enrollment":1299056},{"nctId":"NCT01660204","phase":"NA","title":"Community-Acquired Pneumonia - Study on the Initial Treatment With Antibiotics of Lower Respiratory Tract Infections","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2011-02","conditions":"Community-acquired Pneumonia","enrollment":2283}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17846,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Moxifloxacin or Levofloxacin","genericName":"Moxifloxacin or Levofloxacin","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin and Levofloxacin are broad-spectrum antibiotics that inhibit DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication. Used for Community-acquired pneumonia, Skin and skin structure infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}